Publication:
Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update

Simple item page
dc.contributor.authorElizabeth J. Phillipsen_US
dc.contributor.authorChonlaphat Sukasemen_US
dc.contributor.authorMichelle Whirl-Carrilloen_US
dc.contributor.authorDaniel J. Mülleren_US
dc.contributor.authorHenry M. Dunnenbergeren_US
dc.contributor.authorWasun Chantratitaen_US
dc.contributor.authorBarry Goldspielen_US
dc.contributor.authorYuan Tsong Chenen_US
dc.contributor.authorBruce C. Carletonen_US
dc.contributor.authorAlfred L. Georgeen_US
dc.contributor.authorTaisei Mushirodaen_US
dc.contributor.authorTeri Kleinen_US
dc.contributor.authorRoseann S. Gammalen_US
dc.contributor.authorMunir Pirmohameden_US
dc.contributor.otherDuke University Medical Centeren_US
dc.contributor.otherNorthShore University HealthSystemen_US
dc.contributor.otherVanderbilt University Medical Centeren_US
dc.contributor.otherUniversity of Liverpoolen_US
dc.contributor.otherSt. Jude Children's Research Hospitalen_US
dc.contributor.otherAcademia Sinica Taiwanen_US
dc.contributor.otherUniversity of Torontoen_US
dc.contributor.otherRikenen_US
dc.contributor.otherNIH Clinical Centeren_US
dc.contributor.otherFaculty of Medicine, Ramathibodi Hospital, Mahidol Universityen_US
dc.contributor.otherCentre for Addiction and Mental Healthen_US
dc.contributor.otherNorthwestern University Feinberg School of Medicineen_US
dc.contributor.otherStanford Universityen_US
dc.contributor.otherThe University of British Columbiaen_US
dc.contributor.otherMCPHS Universityen_US
dc.date.accessioned2019-08-28T06:17:25Z
dc.date.available2019-08-28T06:17:25Z
dc.date.issued2018-04-01en_US
dc.description.abstract© 2018 American Society for Clinical Pharmacology and Therapeutics The variant allele HLA-B*15:02 is strongly associated with greater risk of Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in patients treated with carbamazepine or oxcarbazepine. The variant allele HLA-A*31:01 is associated with greater risk of maculopapular exanthema, drug reaction with eosinophilia and systemic symptoms, and SJS/TEN in patients treated with carbamazepine. We summarize evidence from the published literature supporting these associations and provide recommendations for carbamazepine and oxcarbazepine use based on HLA genotypes.en_US
dc.identifier.citationClinical Pharmacology and Therapeutics. Vol.103, No.4 (2018), 574-581en_US
dc.identifier.doi10.1002/cpt.1004en_US
dc.identifier.issn15326535en_US
dc.identifier.issn00099236en_US
dc.identifier.other2-s2.0-85041319988en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/46818
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85041319988&origin=inwarden_US
dc.subjectMedicineen_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleClinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Updateen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85041319988&origin=inwarden_US

Files

Collections

Scopus 2018